HCPCS code S0142: Colistimethate sodium inhalation solution

Key Takeaways

HCPCS code S0142 describes colistimethate sodium inhalation solution administered through durable medical equipment (DME), concentrated form, billed per milligram.

S0142 is a temporary national S-code: Medicaid and private payers accept it, but Medicare Part B does not typically reimburse HCPCS S-codes.

Billing errors often arise from incorrect unit reporting: each unit billed must equal exactly one milligram of colistimethate sodium administered.

Pabau’s claims management software helps DME suppliers and clinics track per-unit drug billing, payer rules, and HCPCS documentation requirements in one place.

HCPCS code S0142 is a HCPCS Level II temporary national code that describes colistimethate sodium, inhalation solution, administered through durable medical equipment, concentrated form, per milligram. According to the Centers for Medicare and Medicaid Services (CMS), S-codes are maintained as temporary national codes for use by non-Medicare payers including Medicaid programs and commercial insurers.

The code has been active since its introduction to the HCPCS S-series and remains current for the 2026 coding year. Every element of the descriptor matters for correct billing: “inhalation solution” distinguishes this from parenteral colistimethate formulations, “administered through durable medical equipment” ties the claim to a qualifying nebulizer, and “concentrated form, per mg” establishes the unit of measure that controls how many units appear on the claim.

DME administration: What qualifies for S0142 billing

The code descriptor specifies “administered through durable medical equipment,” which means the claim is only valid when the inhalation solution is delivered via a qualifying nebulizer system. A standard large-volume nebulizer, a small-volume nebulizer, or an ultrasonic nebulizer can all qualify, provided the equipment itself is separately enrolled and billed through the DME benefit. Billing S0142 for oral or parenteral colistimethate sodium administration is incorrect and will cause claim rejection.

DME suppliers must hold an active Medicare DMEPOS accreditation even for Medicaid and private payer claims, because most state Medicaid programs and commercial payers mirror CMS supplier standards. The supplier’s National Provider Identifier (NPI) must appear on the claim form, and the treating physician’s order must specify the route of administration (inhalation), the drug concentration, and the prescribed dose in milligrams. Incomplete physician orders are the most common upstream cause of S0142 denials.

• Qualifying equipment: Small-volume nebulizer, large-volume nebulizer, ultrasonic nebulizer enrolled under the DME benefit
• Required documentation: Physician order specifying inhalation route, drug concentration, and prescribed dose in mg
• Supplier requirement: Active DME/DMEPOS accreditation and NPI on file with the payer
• Common billing error: Billing S0142 for parenteral or oral colistimethate sodium rather than nebulized inhalation

Payer coverage: Medicaid, private insurers, and Medicare

S-codes are the single most misunderstood category in HCPCS Level II billing. CMS created the S-series as temporary codes for non-Medicare payers, which means Medicare Part B will not process S0142 claims under standard fee-for-service rules.

Submitting S0142 to traditional Medicare Part B will result in a denial. If a patient is dually eligible for Medicare and Medicaid, Medicaid acts as the secondary and the claim routes through Medicaid’s billing system, not Medicare’s.

State Medicaid programs represent the primary payer for HCPCS code S0142. Coverage policies and reimbursement rates vary by state, so billers should verify current fee schedule rates directly with the state Medicaid agency before submitting.

Many commercial and private insurers also accept S-codes, though prior authorization requirements differ by plan. Running insurance eligibility verification before dispensing colistimethate sodium through DME is essential for avoiding after-the-fact denials.

Billing guidelines for HCPCS code S0142

The per-milligram billing unit is where most S0142 claims go wrong. Each unit reported on the claim must represent exactly one milligram of colistimethate sodium that was actually administered to the patient. If the physician prescribes 150 mg per dose, bill 150 units.

Rounding up or estimating units without documentation to support them creates fraud risk under False Claims Act standards. The quantity billed must be reconcilable against the physician’s order, the dispensing record, and the administration record.

Understanding what makes a clean claim is the starting point for S0142 submissions. A complete S0142 claim requires the following elements on the CMS-1450 (UB-04) or CMS-1500 form, depending on the billing entity:

• HCPCS code S0142 in the procedure code field
• Units equal to the exact milligrams administered (not prescribed dose units)
• Date of service matching the administration date
• Diagnosis code(s) establishing medical necessity (see ICD-10 section below)
• Treating physician NPI and ordering physician NPI where required
• Place of service code appropriate to the care setting
• DME supplier NPI and accreditation information

Documentation requirements extend beyond the claim form. Payers may request the physician order, the treatment record showing the nebulizer administration, and proof of DME supplier accreditation during post-payment review. Building a consistent documentation workflow for every S0142 dispensing episode reduces denial management workload downstream. Using structured intake and treatment documentation tools helps standardize what gets captured at the point of care.

Simplify HCPCS billing documentation

Pabau’s claims management tools help DME suppliers and specialty clinics track per-unit drug billing, maintain payer-ready documentation, and reduce claim rejections for complex HCPCS codes like S0142.

Book a demo

OPPS status and outpatient payment system data

Under the Outpatient Prospective Payment System (OPPS), CMS assigns status indicators to HCPCS codes that determine how outpatient facility claims are processed and paid. S0142 carries status indicator designations that reflect its classification as a drug administered through DME in the outpatient setting. Billers at hospital outpatient departments should verify the current OPPS addendum for S0142’s status indicator, as these designations can change with annual OPPS final rules.

The Integrated Outpatient Code Editor (IOCE) processes S0142 claims submitted by outpatient facilities and applies edit logic that checks for correct coding, appropriate diagnosis pairing, and valid modifiers. Claims that fail IOCE edits return with Claim Adjustment Reason Codes (CARCs) that identify the specific edit failure. Reviewing IOCE edit data for S0142 before submitting outpatient facility claims prevents rework. The AAPC HCPCS code reference and the CMS HCPCS overview both provide current code attribute data including OPPS indicators.

ICD-10-CM diagnosis codes commonly paired with S0142

Every S0142 claim requires a diagnosis code that establishes medical necessity for inhaled colistimethate sodium. The treating physician must document the underlying condition in the medical record, and the diagnosis code on the claim must reflect that documentation. Two primary clinical scenarios drive the vast majority of S0142 use: cystic fibrosis with pulmonary involvement, and gram-negative respiratory infections in patients with chronic lung disease or structural airway abnormalities.

The table below lists the ICD-10-CM codes most frequently paired with HCPCS code S0142 based on the clinical conditions for which inhaled colistimethate sodium is commonly prescribed. Medical necessity must be independently documented by the treating provider; coders should not assign diagnosis codes without supporting clinical documentation.

Cystic fibrosis (E84.0) is the dominant indication. Inhaled colistimethate sodium is used to suppress chronic Pseudomonas aeruginosa colonization in CF patients, reducing exacerbation frequency. For non-CF patients, the indication typically involves multidrug-resistant gram-negative organisms where inhaled delivery targets the respiratory tract directly while limiting systemic toxicity. Coders should document the specific organism when known, as this supports the medical necessity argument during payer review. For accurate code lookup, the PGM Billing HCPCS lookup tool provides free reference data.

Clinical context: What is colistimethate sodium and who receives it?

Colistimethate sodium is the prodrug form of colistin, a polymyxin-class antibiotic active against aerobic gram-negative bacteria including Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. It is a last-resort agent typically deployed when multidrug-resistant organisms have exhausted first-line antibiotic options. The inhaled route targets the pulmonary epithelial surface directly, achieving high local drug concentrations while reducing the systemic exposure that drives nephrotoxicity with intravenous colistin.

Understanding the patient population helps coders recognize when S0142 is clinically appropriate versus when a different code may apply. The two primary patient groups are:

• Cystic fibrosis patients: Chronic Pseudomonas colonization is almost universal in adults with CF. Inhaled colistimethate sodium may be prescribed for long-term suppressive therapy or acute exacerbation management, often alongside other inhaled antibiotics such as tobramycin.
• Non-CF bronchiectasis patients: Structural lung disease patients with recurrent gram-negative infections may receive inhaled colistimethate as part of a rotating inhaled antibiotic regimen.
• ICU or post-hospitalization patients: Patients transitioning from IV colistin therapy for MDR gram-negative pneumonia may continue inhaled colistimethate through a home DME nebulizer following discharge.

Coders do not prescribe or recommend treatment. The clinical context here helps ensure the code is applied to the right claims and that the diagnosis pairing reflects the clinical reality documented by the treating physician. Proper medical billing compliance requires that every code on a claim be supported by documentation in the medical record.

Related HCPCS codes for inhaled antibiotics and DME

Several adjacent HCPCS codes appear alongside S0142 in DME and respiratory drug billing. Knowing which code applies to which drug and formulation prevents miscoding and supports accurate billing across the full inhaled antibiotic category. Understanding how superbill documentation captures these related codes keeps the claim set complete when multiple inhaled medications are dispensed in the same episode.

J7682 and J7685 deserve particular attention for CF billing teams. Tobramycin and colistimethate are sometimes alternated on a monthly rotation, which means both codes appear in the same patient record across different dates of service. Verify the dispensing record against the code submitted for each date.

Billing J7682 on a date when colistimethate was actually dispensed is a coding error that payers flag during retrospective audits. For reference, the Medicare Informatics HCPCS code tables provide additional lookup data on HCPCS Level II drug codes.

Common denial patterns and how to resolve them

S0142 claims deny for predictable reasons. Knowing the patterns before submission is more efficient than working denial codes in medical billing after the fact. The three most frequent denial triggers are missing prior authorization, unit count discrepancies, and wrong payer routing.

• Prior authorization missing: Many Medicaid plans and commercial payers require PA for inhaled antibiotics. Obtain authorization before dispensing and document the authorization number on the claim.
• Unit count mismatch: The billed units do not match the administered milligrams documented in the treatment record. Reconcile dispensing logs with claim units before submission.
• Wrong payer routing: Submitting S0142 to Medicare Part B fee-for-service. Route these claims to Medicaid or the commercial plan instead.
• Incomplete physician order: The order does not specify inhalation route, concentration, or milligram dose. Contact the prescribing physician to amend the order before resubmission.
• Diagnosis not supporting medical necessity: The ICD-10 code on the claim does not align with the documented clinical indication for inhaled colistimethate. Review the record and correct the diagnosis pairing.

A strong revenue cycle process for S0142 starts with eligibility verification at the point of order, moves through prior authorization before dispensing, and ends with unit-level reconciliation before claim submission.

Claims management software that tracks these workflow steps reduces the administrative burden on billing teams handling complex drug codes. For deeper context on revenue cycle fundamentals, understanding revenue cycle management helps billing teams frame where S0142 fits in the broader claim lifecycle.

Conclusion

HCPCS code S0142 is a per-milligram inhalation drug code that sits entirely outside Medicare Part B reimbursement. Accurate billing depends on three things: confirming the right payer (Medicaid or commercial), documenting the exact milligrams administered, and pairing the claim with a diagnosis code that reflects the treating physician’s documented clinical indication.

Pabau’s digital documentation tools help clinics and DME suppliers capture treatment records, physician orders, and administered doses in a structured format that supports clean HCPCS claims. To see how Pabau handles complex billing workflows, book a demo with the team.

Continue your research

Want to reduce claim rejections across your HCPCS billing? What is medical billing explains the full lifecycle from documentation through reimbursement.

Seeing denials on drug claims? Denial management in healthcare covers systematic approaches to reducing and recovering rejected claims.

Need a billing compliance checklist? Medical billing compliance outlines documentation and audit requirements for specialty drug billing.

Frequently Asked Questions